Social Health and Quality of Life in Young Adult Breast Cancer Survivors

This study is looking at how social relationships, like friendships and family connections, affect the physical activity and overall well-being of young adults who have survived breast cancer. Researchers want to understand how these relationships change after a cancer diagnosis and how those changes might impact healthy behaviors. You could be eligible if you are between 18 and 39 years old, were diagnosed with Stage I or II breast cancer (or certain Stage III cases), and were treated at USC hospitals. The main goals are to track changes in social health, physical activity, and quality of life over one year. The information gathered will help develop better support programs for young cancer patients in the future.

Study design
This is an observational study planning to enroll 250 participants. It is not a drug trial and does not involve a specific treatment.
What's involved
You would complete surveys over 40 minutes and wear an accelerometer (a device that measures movement) for 7 continuous days at the start of the study, and then again at 3, 6, and 12 months.
Compensation
Not stated in the trial record.
Follow-up
Your social health, physical activity, and quality of life will be tracked for up to one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07259304

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

Active, Not Recruiting
Not specifiedAges 18–39Observational
University of Southern California
~118 participants
Updated 2026-07-31 on ClinicalTrials.gov
What's tested:Medical Device Usage and EvaluationQuality-of-Life AssessmentSurvey Administration

At a glance

Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in social role functioning
Measured over Baseline up to 1 year
+10 more outcomes measured
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Anatomic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Central Nervous System Neoplasm
Clinical Stage I Cutaneous Melanoma AJCC v8
Clinical Stage IA Cutaneous Melanoma AJCC v8
Clinical Stage IB Cutaneous Melanoma AJCC v8
Clinical Stage II Cutaneous Melanoma AJCC v8
Clinical Stage IIA Cutaneous Melanoma AJCC v8
Clinical Stage IIB Cutaneous Melanoma AJCC v8
Clinical Stage IIC Cutaneous Melanoma AJCC v8
Clinical Stage III Cutaneous Melanoma AJCC v8
Hodgkin Lymphoma
Malignant Bone Neoplasm
Malignant Brain Neoplasm
Malignant Solid Neoplasm
Malignant Testicular Neoplasm
Non-Hodgkin Lymphoma
Pathologic Stage I Cutaneous Melanoma AJCC v8
Pathologic Stage IA Cutaneous Melanoma AJCC v8
Pathologic Stage IB Cutaneous Melanoma AJCC v8
Pathologic Stage II Cutaneous Melanoma AJCC v8
Pathologic Stage IIA Cutaneous Melanoma AJCC v8
Pathologic Stage IIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIC Cutaneous Melanoma AJCC v8
Pathologic Stage III Cutaneous Melanoma AJCC v8
Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Prognostic Stage I Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8
Prognostic Stage IB Breast Cancer AJCC v8
Prognostic Stage II Breast Cancer AJCC v8
Prognostic Stage IIA Breast Cancer AJCC v8
Prognostic Stage IIB Breast Cancer AJCC v8
Prognostic Stage III Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage IIIB Breast Cancer AJCC v8
Prognostic Stage IIIC Breast Cancer AJCC v8
Stage I Cervical Cancer AJCC v8
Stage I Colorectal Cancer AJCC v8
Stage I Differentiated Thyroid Gland Carcinoma AJCC v8
Stage I Ovarian Cancer AJCC v8
Stage I Thyroid Gland Medullary Carcinoma AJCC v8
Stage I Uterine Corpus Cancer AJCC v8
Stage IA Cervical Cancer AJCC v8
Stage IA Ovarian Cancer AJCC v8
Stage IA Uterine Corpus Cancer AJCC v8
Stage IA1 Cervical Cancer AJCC v8
Stage IA2 Cervical Cancer AJCC v8
Stage IB Cervical Cancer AJCC v8
Stage IB Ovarian Cancer AJCC v8
Stage IB Uterine Corpus Cancer AJCC v8
Stage IB1 Cervical Cancer AJCC v8
Stage IB2 Cervical Cancer AJCC v8
Stage IC Ovarian Cancer AJCC v8
Stage II Cervical Cancer AJCC v8
Stage II Colorectal Cancer AJCC v8
Stage II Differentiated Thyroid Gland Carcinoma AJCC v8
Stage II Ovarian Cancer AJCC v8
Stage II Thyroid Gland Medullary Carcinoma AJCC v8
Stage II Uterine Corpus Cancer AJCC v8
Stage IIA Cervical Cancer AJCC v8
Stage IIA Colorectal Cancer AJCC v8
Stage IIA Ovarian Cancer AJCC v8
Stage IIA1 Cervical Cancer AJCC v8
Stage IIA2 Cervical Cancer AJCC v8
Stage IIB Cervical Cancer AJCC v8
Stage IIB Colorectal Cancer AJCC v8
Stage IIB Ovarian Cancer AJCC v8
Stage IIC Colorectal Cancer AJCC v8
Stage III Cervical Cancer AJCC v8
Stage III Colorectal Cancer AJCC v8
Stage III Differentiated Thyroid Gland Carcinoma AJCC v8
Stage III Ovarian Cancer AJCC v8
Stage III Thyroid Gland Medullary Carcinoma AJCC v8
Stage III Uterine Corpus Cancer AJCC v8
Stage IIIA Cervical Cancer AJCC v8
Stage IIIA Colorectal Cancer AJCC v8
Stage IIIA Ovarian Cancer AJCC v8
Stage IIIA Uterine Corpus Cancer AJCC v8
Stage IIIA1 Ovarian Cancer AJCC v8
Stage IIIA2 Ovarian Cancer AJCC v8
Stage IIIB Cervical Cancer AJCC v8
Stage IIIB Colorectal Cancer AJCC v8
Stage IIIB Ovarian Cancer AJCC v8
Stage IIIB Uterine Corpus Cancer AJCC v8
Stage IIIC Colorectal Cancer AJCC v8
Stage IIIC Ovarian Cancer AJCC v8
Stage IIIC Uterine Corpus Cancer AJCC v8
Stage IIIC1 Uterine Corpus Cancer AJCC v8
Stage IIIC2 Uterine Corpus Cancer AJCC v8
3 sites across 2 states
California2
Texas1
  • Kimberly Miller, PhD · PRINCIPAL_INVESTIGATOR · University of Southern California

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18-39 years at cancer diagnosis.
Newly diagnosed (within past 3 months) with one of the following cancer types commonly seen in AYAs: testis, breast, thyroid, cervix, colorectal, brain/central nervous system, non Hodgkin lymphoma, uterine, melanoma, bones and joints, ovary, Hodgkin lymphoma, lung, or gastric cancer.
Stage I-IV for solid tumors (AJCC 8th edition TNM staging) or I-IV for lymphomas (Ann Arbor staging).
Receiving care at a participating USC affiliated hospital (USC Norris Comprehensive Cancer Center, Keck Hospital of USC, or Los Angeles General Medical Center) or MD Anderson Cancer Center.
Clinician assessed expected survival greater than 12 months at time of diagnosis.
Able to complete questionnaires and wear a wrist worn accelerometer.
English or Spanish speaking.

Exclusion

Leukemia (excluded due to longer treatment duration and different care trajectory).
Primary language other than English or Spanish.
Cognitive or physical limitations that preclude completion of surveys or wearing an accelerometer.
  • Change in social role functioningBaseline up to 1 year

    Assessed using the PROMIS Ability to Participate in Social Roles and Activities Short Form 4a, which measures limitations in participation in usual social roles and activities due to health (higher scores indicate better participation).

  • Change in perceived emotional supportBaseline up to 1 year

    Assessed using the PROMIS Emotional Support Short Form 4a, which measures perceived availability of people who provide emotional support, such as care, understanding, and someone to listen (higher scores indicate more emotional support).

  • Change in perceived informational supportBaseline up to 1 year

    Assessed using the PROMIS Informational Support Short Form 4a, which measures perceived availability of people who provide advice, information, and guidance (higher scores indicate more informational support).

  • Change in perceived instrumental supportBaseline up to 1 year

    Assessed using the PROMIS Instrumental Support Short Form 4a, which measures perceived availability of people who provide practical help and assistance with tasks (higher scores indicate more instrumental support).

  • Change in loneliness scoreBaseline up to 1 year

    Assessed using the UCLA Loneliness Scale short form, which measures subjective feelings of loneliness and social disconnection (higher scores indicate greater loneliness).

  • Change in social anxiety symptomsBaseline up to 1 year

    Assessed using the Mini Social Phobia Inventory (Mini SPIN), a brief validated measure of social anxiety and fear of social interactions (higher scores indicate greater social anxiety).

  • Change in social network densityBaseline up to 1 year

    Assessed using a study developed egocentric social network questionnaire in which participants list up to 10 important adult social contacts and indicate which contacts know each other; density is calculated as the proportion of possible ties that are present (higher values indicate a more densely connected network).

  • Change in proportion of supportive social tiesBaseline up to 1 year

    Assessed using a study developed egocentric social network questionnaire that measures whether each named social contact provides social support and encouragement for physical activity; the outcome is the proportion of social ties providing support (higher values indicate a more supportive network).

  • Change in frequency of social contactBaseline up to 1 year

    Assessed using a study developed egocentric social network questionnaire that captures how often participants interact with each named social contact; the outcome is the average reported frequency of contact across alters (higher values indicate more frequent social contact).

  • Change in total daily physical activityBaseline up to 1 year

    Assessed using a wrist worn ActiGraph GT3X BT accelerometer worn for 7 consecutive days at each time point. Raw data are converted to monitor independent movement summary (MIMS) units, and total daily physical activity is represented by average daily MIMS units across valid wear days (higher values indicate more physical activity).

  • Change in total daily sedentary timeBaseline up to 1 year

    Assessed using a wrist worn ActiGraph GT3X BT accelerometer worn for 7 consecutive days at each time point. Sedentary time is calculated from accelerometer data as average minutes per day spent in sedentary behavior (e.g., low movement periods while awake) across valid wear days (higher values indicate more sedentary time).